JP2022538338A5 - - Google Patents

Info

Publication number
JP2022538338A5
JP2022538338A5 JP2021577856A JP2021577856A JP2022538338A5 JP 2022538338 A5 JP2022538338 A5 JP 2022538338A5 JP 2021577856 A JP2021577856 A JP 2021577856A JP 2021577856 A JP2021577856 A JP 2021577856A JP 2022538338 A5 JP2022538338 A5 JP 2022538338A5
Authority
JP
Japan
Prior art keywords
rilpivirine
pharmaceutically acceptable
acceptable salt
less
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021577856A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538338A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/068734 external-priority patent/WO2021001508A1/en
Publication of JP2022538338A publication Critical patent/JP2022538338A/ja
Publication of JP2022538338A5 publication Critical patent/JP2022538338A5/ja
Withdrawn legal-status Critical Current

Links

JP2021577856A 2019-07-03 2020-07-02 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法 Withdrawn JP2022538338A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962870413P 2019-07-03 2019-07-03
US62/870,413 2019-07-03
PCT/EP2020/068734 WO2021001508A1 (en) 2019-07-03 2020-07-02 Methods of treating hiv in pediatric patients with rilpivirine

Publications (2)

Publication Number Publication Date
JP2022538338A JP2022538338A (ja) 2022-09-01
JP2022538338A5 true JP2022538338A5 (enExample) 2023-07-11

Family

ID=71579550

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021577856A Withdrawn JP2022538338A (ja) 2019-07-03 2020-07-02 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法
JP2021577871A Withdrawn JP2022538449A (ja) 2019-07-03 2020-07-03 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021577871A Withdrawn JP2022538449A (ja) 2019-07-03 2020-07-03 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Country Status (14)

Country Link
US (3) US20210000823A1 (enExample)
EP (2) EP3993799A1 (enExample)
JP (2) JP2022538338A (enExample)
KR (2) KR20220028049A (enExample)
CN (2) CN114126655A (enExample)
AU (2) AU2020300818A1 (enExample)
BR (2) BR112021026916A2 (enExample)
CA (1) CA3144307A1 (enExample)
IL (1) IL289457A (enExample)
JO (1) JOP20210347A1 (enExample)
MA (2) MA56449A (enExample)
MX (2) MX2022000060A (enExample)
PH (1) PH12021553288A1 (enExample)
WO (2) WO2021001508A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538338A (ja) * 2019-07-03 2022-09-01 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
JP2014500261A (ja) * 2010-11-19 2014-01-09 ギリアード サイエンシーズ， インコーポレイテッド リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
PT4070788T (pt) * 2015-06-30 2023-06-06 Gilead Sciences Inc Formulações farmacêuticas
US11065198B2 (en) * 2016-10-24 2021-07-20 Janssen Sciences Ireland Unlimited Company Dispersible compositions
CN110958883A (zh) * 2017-06-30 2020-04-03 Viiv保健公司 组合及其用途和疗法
JP2022538338A (ja) * 2019-07-03 2022-09-01 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Similar Documents

Publication Publication Date Title
JP6196041B2 (ja) 大うつ病を有する患者において減量療法を提供する方法
Taha et al. Parenteral patent drug S/GSK1265744 has the potential to be an effective agent in pre-exposure prophylaxis against HIV infection
JP2017514911A5 (enExample)
JP2022538338A5 (enExample)
KR20260046169A (ko) Hiv의 치료 및 예방을 위한 레나카파비르 주간 투여 레지먼
JP2022538449A5 (enExample)
US20190151307A1 (en) Methods of treating patients co-infected with a virus and tuberculosis
AU2002332610B2 (en) Use of atazanavir in HIV therapy
JP2020527570A (ja) 組み合わせ薬物療法
JP2020528409A5 (enExample)
EP3600332B1 (en) Hiv post-exposure prophylaxis
WO2008043829A2 (en) Method for treating hiv-1 infection by the combined administration of nevirapine, tenofovir and emtricitabine
RU2022102380A (ru) Способы лечения инфекции, вызванной вич, у пациентов детского возраста с применением рилпивирина
CN117858705A (zh) 使用抗病毒化合物和硝唑尼特进行治疗
Kobayashi et al. A case of under-dosing after raltegravir formulation change in an elderly patient treated for HIV
US20260048058A1 (en) Valacyclovir and celecoxib for the treatment of alzheimer's disease and covid-19
US20250186443A1 (en) Valacyclovir and celecoxib in combination with nirmatrelvir and ritonavir for the treatment of covid-19
CA3113011C (en) Integrase inhibitors for the prevention of hiv
Francisco Data Released from Startmrk Study of Isentress Versus Efavirenz
CA3054822C (en) Hiv post-exposure prophylaxis
JP2023527798A (ja) ＣＯＶＩＤ－１９（ＳＡＲＳ－ＣｏＶ－２）を含むＲＮＡウイルス感染を治療するための方法
Bowersox ACTG 343: three drugs better than two for maintaining HIV suppression
SINGH et al. Novel Role of Combination Therapy of Lamivudine and Zidovudine Antiretroviral Drugs in Elevating The Efficiency
JP2019508399A (ja) 多くの治療を経験したｈｉｖ−１に感染した個体において使用するためのホステムサビル
EA049592B1 (ru) СПОСОБ ЛЕЧЕНИЯ РНК ВИРУСНЫХ ИНФЕКЦИЙ, В ТОМ ЧИСЛЕ COVID-19 (SARS-CoV-2)